Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 7Recruiting 3Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Follicular 2Recurrence 1Neoplasms 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × abexinostat × Clear all
NCT03600441 2025-04-10

FORERUNNER

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting
139 enrolled
Lymphoid

Lymphoma, Follicular, Neoplasms

NCT03934567 2025-04-10

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting
87 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT04024696 2025-04-10

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Xynomic Pharmaceuticals, Inc.

Phase 1/2 Active not recruiting
12 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡